Literature DB >> 2567265

Do H2 receptor antagonists have to be given at night? A study of the antisecretory profile of SKF 94482, a new H2 receptor antagonist which has a profound effect on daytime acidity.

S G Chiverton1, D W Burget, R H Hunt.   

Abstract

Evening dosing has become standard for H2 receptor antagonists, because available agents inhibit nocturnal basal acid secretion more effectively than daytime stimulated secretion. We studied the optimal time of administration of a new high affinity long acting H2 receptor antagonist, SKF 94482, for the suppression of intragastric acidity using intragastric telemetry. Sixteen healthy subjects received SKF 94482 200 mg or placebo at 07:30, 17:30, and 21:30 h during four separate studies. Time (h) above pH 4 was (mean (SD] 1.1 (1.2) on placebo, 7.8 (5.0) on SKF 94482 given at 07:30, 5.75 (3.6) on SKF 94482 given at 17:30, and 6.1 (2.9) when given at 21:30. All treatment regimens were effective in increasing time above pH 4 (p less than 0.01). The efficacy of the morning dose of SKF 94482 indicates that the best time to give H2 receptor antagonists depends on their pharmacological properties.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2567265      PMCID: PMC1434200          DOI: 10.1136/gut.30.5.594

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats.

Authors:  H Larsson; E Carlsson; H Mattsson; L Lundell; F Sundler; G Sundell; B Wallmark; T Watanabe; R Håkanson
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

2.  Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole.

Authors:  S Lanzon-Miller; R E Pounder; M R Hamilton; S Ball; N A Chronos; F Raymond; M Olausson; C Cederberg
Journal:  Aliment Pharmacol Ther       Date:  1987-06       Impact factor: 8.171

3.  Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial.

Authors:  K Lauritsen; S J Rune; P Bytzer; H Kelbaek; K G Jensen; J Rask-Madsen; F Bendtsen; J Linde; M Højlund; H H Andersen
Journal:  N Engl J Med       Date:  1985-04-11       Impact factor: 91.245

4.  Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer.

Authors:  T Gledhill; O M Howard; M Buck; A Paul; R H Hunt
Journal:  Gut       Date:  1983-10       Impact factor: 23.059

5.  A frequency-duration index (FDI) for the evaluation of ambulatory recordings of gastro-oesophageal reflux.

Authors:  F J Branicki; D F Evans; J A Jones; A L Ogilvie; M Atkinson; J D Hardcastle
Journal:  Br J Surg       Date:  1984-06       Impact factor: 6.939

6.  Experimental gastric carcinogenesis in the rat: effects of hypergastrinemia and acid secretion.

Authors:  C W Deveney; H Freeman; L W Way
Journal:  Am J Surg       Date:  1980-01       Impact factor: 2.565

7.  Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.

Authors:  B K Sharma; R P Walt; R E Pounder; M D Gomes; E C Wood; L H Logan
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

8.  Comparison of cimetidine 800 mg once daily and 400 mg twice daily in acute duodenal ulceration.

Authors:  L Capurso; P R Dal Monte; F Mazzeo; G Menardo; A Morettini; A Saggioro; G Tafner
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-24

9.  Enhanced effect of gastrin on rat stomach carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  E Tahara; F Shimamoto; K Taniyama; H Ito; Y Kosako; H Sumiyoshi
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

10.  Ranitidine 150 mg twice daily vs 300 mg nightly in treatment of duodenal ulcers.

Authors:  A Ireland; D G Colin-Jones; P Gear; P L Golding; J K Ramage; J G Williams; R J Leicester; C L Smith; G Ross; J Bamforth
Journal:  Lancet       Date:  1984-08-04       Impact factor: 79.321

View more
  2 in total

Review 1.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

2.  Helicobacter pylori and luminal gastric pH. Relationships in nonulcer dyspepsia.

Authors:  P Bechi; R Dei; A Amorosi; G Marcuzzo; C Cortesini
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.